VFI is pleased to announce its continued partnership with VIDO, thanks to a 5M USD award from CEPI (Coalition of Epidemics Preparedness Innovations), to develop new vaccines that are broadly protective against COVID-19 variants and suitable for use in Low- and Middle-Income Countries. This work builds on the development of COVAC-2, VIDO’s subunit vaccine formulated with Sepivac SWE™, an adjuvant co-developed by Seppic and VFI.
News and releases
USask’s VIDO announces positive Phase 1 results for COVAC-2
VFI is pleased to share news on positive Phase 1 results for COVAC-2, a COVID-19 subunit vaccine candidate developed by Usask's VIDO, formulated with Sepivac SWE™️, an adjuvant developed by VFI and Seppic. Click here to read the press release.
VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval
VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval for subunit-based vaccine combined to the open-access adjuvant Sepivac SWE, that was developed by Seppic in collaboration with VFI. First-in-human trials are planned in January 2021.
The Vaccine Formulation Institute’s squalene-in-water adjuvant SWE is now available from our partner Seppic under the name Sepivac SWE™
Sepivac SWE™ is prepared at cGMP-grade and is being made available to the entire vaccine community under open-access terms. Sepivac SWE™ adjuvant can be used in the composition of several vaccines including vaccines against seasonal influenza, pandemic influenza and COVID-19. A production capacity of several hundred million doses per year of Sepivac SWE™ is expected by summer 2021.
VFI is proud to have co-led the development of the first open-access adjuvant for prophylactic use since aluminium salts in the 1920’s and is grateful to its initial funders (European Commission, US-HHS BARDA and GIZ) for having catalysed the development of the SWE adjuvant. We look forward to continuing this long-term partnership with our Seppic colleagues.
VFI’s fight against Coronavirus during 2nd wave of COVID pandemic
With fitting measures, VFI laboratories will remain operational during the second wave of COVID-19 pandemic. We continue our vaccine development efforts in collaboration with the Bill & Melinda Gates Foundation and other partners in order to develop rapid solutions against the pandemic.
Webinar: Regulatory information for veterinary vaccine development in the EU and where to find it:
As partner of ENOVA and TRANSVAC, VFI is organizing this joined webinar, open to interested people working in the field of veterinary vaccine development.
10th call for TRANSVAC vaccine development services (TNA)
Deadline 15. December 2020
Access to VFI's Adjuvants and Formulation Services – free of charge.
For more information on VFI services get in touch: email@example.com
Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. To facilitate access to these skills and capacities, TRANSVAC2 offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease area.
- Services will be offered free of charge, with few exceptions!
- Academic and non-academic research groups, SMEs and industries can apply!
- Submission deadline: 15 October 2020
For further information on services available and how to apply please visit www.transvac.org
New review article “Modulation of immune responses using adjuvants to facilitate therapeutic vaccination”
New review article “Technological Approaches for Improving Vaccination Compliance and Coverage”
VFI and Seppic announce co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines (including COVID-19 vaccines) on an open-access basis
VFI and Seppic announced that they have finalized the development of an oil-in-water adjuvant at a Seppic plant in France. The adjuvant, manufactured under Good Manufactured Practices, will be openly available from Seppic before the end of this year, for the entire vaccine community.
VFI supports Sars-Cov-2 vaccine development through TRANSVAC2 (European Commission)
As partner of TRANSVAC2, VFI offers its adjuvant and formulation services to vaccine researchers and developers in the context of Covid-19. Vaccine researchers and developers can ship their Sars-Cov-2 vaccine antigens to VFI for formulation with adjuvants suitable for clinical use. Once optimal formulations are identified, VFI can perform immunogenicity studies in mice including analyses of B- and T-cell responses. First deadline for application is 15 April 2020.
VFI supports Sars-Cov-2 vaccine development through GH-VAP (Bill & Melinda Gates Foundation)
VFI is working with grantees from the Bill & Melinda Gates Foundation (BMGF) to evaluate Sars-Cov-2 vaccine candidates. Antigens provided by BMGF grantees are appropriately formulated with adjuvants developed by VFI with the ultimate goal to identify suitable Sars-Cov-2 vaccine candidates which can progress towards the clinic. This work is supported by the Global Health Vaccine Accelerator Platforms (GH-VAP) funded by BMGF.
VFI will actively support the development of vaccines against Covid-19
VFI will support the vaccine community during Covid-19 pandemic. VFI is currently manufacturing several adjuvants to be included in upcoming Covid-19 studies and has secured access to animal facilities for immunogenicity studies of adjuvanted-Sars-Cov-2 vaccine formulations. VFI is also setting up collaborations with numerous vaccine developers worldwide in order to formulate Sars-Cov-2 vaccine candidates with VFI adjuvants to induce relevant immune responses.
6th call for TRANSVAC vaccine development services (TNA)
Access to VFI's adjuvants and formulation services – free of charge.
TRANSVAC project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.
Services are offered free of charge! Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country. Submission deadline: 05. August 2019
APPLICATION FORM can be found here.
For services related information please contact the TRANSVAC2 team (firstname.lastname@example.org) or service providers.
5th call for TRANSVAC: European training in vaccinology
Deadline for applications 1 July 2019
The fifth call is open until 1st July 2019. It covers 3 modules:
- M10 - Assay Development and Validation - Application of SPR Technologies in Vaccine Development and Manufacturing conducted at Fraunhofer IME, Aachen Germany (10-11 October 2019)
- M11 - Process Development and scale-up of recombinant protein vaccines organized also by Fraunhofer IME, Aachen Germany (7-8 October 2019)
- M12 - Requirements for GMP production, also by Fraunhofer IME, Aachen Germany (14–15 October 2019)
For training related information please contact the TRANSVAC team at email@example.com
4th Call for TRANSVAC: European Training in Vaccinology
Deadline for applications 01. June 2019
The fourth call is open from 01. April 2019 – 01. June 2019. It covers 3 modules:
- M6 – CyTOF (Cytometry by time‐of‐flight) conducted at CEA, Fontenay-aux-Roses, France (19-20 September 2019)
- M7 – Flow Cytometry organized also by CEA, Fontenay-aux-Roses, France (18-19 September 2019)
- M9 … Key considerations and best practices for viral vaccine process development, scale-up and implementation at manufacturing scale including single use technologies, organized by VFI together with Merck at Merck/M Lab permises in Molsheim, France (10-11 September 2019)
Participants will be selected by a course selection panel.
The course is offered free of charge. However selected applicants will have to cover their own travel and visa expenses and accommodation (excluding M9, where accommodation will be provided by organizers). Candidates working in a European Union Member State or Associated Member State as well as candidates from other countries who are working in vaccine development projects funded by the European Commission (EC) or European and Developing Countries Clinical trial Partnership (EDCTP) are eligible to apply. Other candidates can also apply, but priority will be given to the groups mentioned above.
For more information about the training modules offered by TRANSVAC, the eligibility criteria and the application process, please visit: www.transvac.org
If you have any specific questions, you can contact the project management team at: firstname.lastname@example.org